Clinical Characteristics and Mechanism Research of Inhibitors of Janus Kinase in the Idiopathic Inflammatory Myopathies

Sponsor
Peking University People's Hospital
Study ID
NCT05400889
Phase
PHASE2
Status
Unknown

Conditions

  • Idiopathic Inflammatory Myopathies

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • tofacitinib — DRUG
    Tofacitinib 5mg was taken orally once or twice a day and baricitinib 2mg or 4mg was taken orally once a day for 6 months.

Study Details

This study aims to explore the clinical characteristics and mechanism of inhibitors of janus kinase in the treatment of idiopathic inflammatory myopathies

Key Dates

Start date
Jun 10, 2022
Status verified
Oct 2022
Primary completion
Mar 1, 2023
Completion
Jun 1, 2023

Study Design

Enrollment
10 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: tofacitinib or baricitinib
    Tofacitinib 5mg was taken orally once or twice a day and baricitinib 2mg or 4mg was taken orally once a day for 6 months.

Primary Outcome Measure

Immunological Responses [ Time Frame: week 24 ]

Central Contacts

Related Studies